The in vitro toxicology testing market is expected to reach USD 8.74 Billion by 2022 from an estimated USD 6.34 Billion in 2017, at a CAGR of 6.6%.
Seattle, WA -- (SBWIRE) -- 10/11/2017 -- The report "In Vitro Toxicology Testing Market by Products (Assays) & Services, Toxicity Endpoints & Tests (ADME, Skin, Genotoxicity, Organ Toxicity), Technology (Cell-based, HTS), Method (Cellular Assays, Ex-Vivo), Industry (Pharmaceutical, Cosmetics) - Forecast to 2022", The in vitro toxicology testing market is expected to reach USD 8.74 Billion by 2022 from an estimated USD 6.34 Billion in 2017, at a CAGR of 6.6%. The key factors driving the growth of this market include opposition to animal testing, growing demand for in vitro technology in the European market, new and promising technologies, and increasing R&D expenditure to detect toxicity at an early stage.
Browse 139 Market Data Tables and 32 Figures spread through 253 Pages and in-depth TOC on "In Vitro Toxicology Testing Market"
Early buyers will receive 10% customization on reports.
By Toxicity Endpoints and Tests, ADME hold the largest market share in 2017
Based on toxicity endpoints and tests of in vitro toxicology testing, the market is subsegmented into ADME, genotoxicity, skin irritation and sensitization, cytotoxicity, ocular toxicity, organ toxicity, phototoxicity, dermal toxicity, and other toxicities (eco toxicity, endocrine disruption, and reproductive & developmental toxicity). In 2017, the ADME segment is expected to account for the largest share of the global in vitro toxicology testing market owing to its highly reproducible & accurate data and the increasing demand to curb drug toxicity at the drug development phase.
Cell culture technology to hold the largest market share in 2017
Based on technology, the in vitro toxicology testing market is segmented into cell culture technologies, high-throughput technologies, cellular imaging technologies, and toxicogenomics. The toxicogenomics segment is expected to account for the highest CAGR in the global in the vitro toxicology testing market. Toxicogenomics is preferred to elucidate the changes in gene expression in response to toxic exposure and facilitates to identify toxicity pathways.
Download PDF Brochure:- http://www.marketsandmarkets.com/pdfdownload.asp?id=209577065
US expected to hold the largest share of the in vitro toxicology testing market in 2017
US is estimated to account for the largest share among other regions in the in vitro toxicology testing market, followed by Germany and UK. In the Asia Pacific region, China is expected to grow at the highest CAGR during the forecast period.
The major players in the global in vitro toxicology testing market include Cyprotex (An Evotec AG subsidiary, Germany), Covance (A Laboratory Corporations of America Holding's subsidiary, US), Eurofins Scientific SE (Luxembourg), GE Healthcare (US), Thermo Fisher Scientific (US), SGS SA (Switzerland), Promega Corporation (US), Merck KGaA (Germany), Charles River Laboratories, Inc. (US), and Lonza Group Ltd. (Switzerland), among others.
Companion Diagnostics Market by Technology (PCR, IHC, NGS, ISH), Indication (Breast cancer, NSCLC, Colorectal cancer, Neurological disorders, Infectious Diseases), End User (Pharmaceutical & Biopharmaceutical Companies, Reference Lab) - Global Forecast to 2022
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
701 Pike Street,
Suite 2175, Seattle,
WA 98101, United States